<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00971399</url>
  </required_header>
  <id_info>
    <org_study_id>RMS vs ODS for CRINV</org_study_id>
    <secondary_id>0808-011-252</secondary_id>
    <nct_id>NCT00971399</nct_id>
  </id_info>
  <brief_title>Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting</brief_title>
  <official_title>Phase III Prospective Randomized Trial Comparing Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting in the Treatment of Gastrointestinal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        1. To compare prophylactic effect of ondansetron versus ramosetron on radiotherapy induced
           nausea and vomiting in the treatment of gastrointestinal cancer.

        2. To verify an improvement of 20% in complete response rate in term of radiotherapy
           induced nausea and vomiting (from 60% with ondansetron to 80% with ramosetron).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response of RINV (no vomiting and no rescue medication)</measure>
    <time_frame>4 weeks after medication</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Radiotherapy Induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>RMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ramosetron 0.1mg q.d. SL on D1-5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ODS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ondansetron 8mg, b.i.d SL on D1-5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramosetron</intervention_name>
    <description>ramosetron 0.1mg q.d. SL on D1-5</description>
    <arm_group_label>RMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
    <description>ondansetron 8mg, b.i.d SL on D1-5</description>
    <arm_group_label>ODS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AJCC 1-3 staged gastrointestinal cancer patient

          -  patient undergoing radiotherapy as treatment

          -  age 20 yr and higher

          -  ECOG 0-2

        Exclusion Criteria:

          -  age &lt; 20

          -  ECOG 3-4

          -  patient experiencing nausea or vomiting prior to accrual

          -  patient under antiemetic medication

          -  patient under steroid medication (topical or inhalant steroid application are
             exceptional)

          -  patient under opioid medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Kim K, Chie EK, Jang JY, Kim SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. Jpn J Clin Oncol. 2009 Feb;39(2):111-5. doi: 10.1093/jjco/hyn140. Epub 2008 Dec 5.</citation>
    <PMID>19060294</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2009</study_first_submitted>
  <study_first_submitted_qc>September 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2009</study_first_posted>
  <last_update_submitted>February 24, 2011</last_update_submitted>
  <last_update_submitted_qc>February 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Eui Kyu Chie/Assistant Clinical Professor</name_title>
    <organization>Department of Radiation Oncology, Seoul National University Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Ramosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

